Deep Dive: DMT What Works (and What Doesn't) Ep03

1. The Origin Story — Why Coagulation?

Coagulation became the natural birthplace of DMTs because hematology was merging with oncology in the 1980s, leaving bleeding disorders to pathology. This created a perfect storm: clinicians didn’t understand coagulation tests, but needed them urgently. The gap between complex lab data and clinical interpretation created the need for expert interpretation teams.

2. The Core Problem DMTs Solve

Diagnostic uncertainty is the primary driver for DMTs. Clinicians often guess at routine test results—immature platelet fraction, Apo E4 subtypes—because they lack expertise. DMTs provide the “place to go” when clinicians say, “I don’t know,” but need answers for patient care.

3. What Works — Successful DMT Models

COVID DMT: Built 75 → 150 interpretive reports integrating PCR, antibody, and rapid test data. It actually reduced mortality and length of stay, but was shut down after four years due to political pressure. Rare Disease Economics: PKU—6 genes, 1,200+ mutations—with new small-molecule therapy. Lab expertise saves lives from birth. Chain of Reasoning: A teaching tool that makes every patient case a learning moment. Vanderbilt’s CMO reported that this transforms resident education. Resource Management DMT: Platelet refractoriness team at Emory—logistics and resource optimization as clinical diagnosis.

4. What Doesn’t Work — Failed DMT Models

DMTs started by people who don’t know the specialty deeply. Ideas like a “fatty liver DMT” that require expensive equipment most institutions can’t afford. Projects forced by administrators without clinical expertise or commitment.

5. The Three Questions for Starting a DMT

Commitment: Can you do it Monday through Friday? Weekend cases will pile up. Knowledge: Do you know enough about this area to lead it? Succession: Who does it when you’re gone? Build redundancy before starting.

6. The Real Value Proposition

DMTs aren’t just cost-cutting tools—they’re clinical value creators. They improve diagnosis speed and accuracy. They teach clinicians at the point of care. They create institutional knowledge that persists beyond individual experts.

Bottom Line Start DMTs only in areas you know deeply, commit to daily operation, build redundancy, and focus on clinical impact rather than administrative metrics. The most successful DMTs solve real diagnostic uncertainty while teaching the next generation of clinicians.

1. The Origin Story — Why Coagulation?

• Coagulation became the natural birthplace of DMTs because hematology was merging with oncology in the 1980s, leaving bleeding disorders to pathology.
• This created a perfect storm: clinicians didn’t understand coagulation tests, but needed them urgently.
• The gap between complex lab data and clinical interpretation created the need for expert interpretation teams.

2. The Core Problem DMTs Solve

• Diagnostic uncertainty is the primary driver for DMTs.
• Clinicians often guess at routine test results—immature platelet fraction, Apo E4 subtypes—because they lack expertise.
• DMTs provide the “place to go” when clinicians say, “I don’t know,” but need answers for patient care.

3. What Works — Successful DMT Models

• COVID DMT: Built 75 → 150 interpretive reports integrating PCR, antibody, and rapid test data. It actually reduced mortality and length of stay, but was shut down after four years due to political pressure.
• Rare Disease Economics: PKU—6 genes, 1,200+ mutations—with new small-molecule therapy. Lab expertise saves lives from birth.
• Chain of Reasoning: A teaching tool that makes every patient case a learning moment. Vanderbilt’s CMO reported that this transforms resident education.
• Resource Management DMT: Platelet refractoriness team at Emory—logistics and resource optimization as clinical diagnosis.

4. What Doesn’t Work — Failed DMT Models

• DMTs started by people who don’t know the specialty deeply.
• Ideas like a “fatty liver DMT” that require expensive equipment most institutions can’t afford.
• Projects forced by administrators without clinical expertise or commitment.

5. The Three Questions for Starting a DMT

• Commitment: Can you do it Monday through Friday? Weekend cases will pile up.
• Knowledge: Do you know enough about this area to lead it?
• Succession: Who does it when you’re gone? Build redundancy before starting.

6. The Real Value Proposition

• DMTs aren’t just cost-cutting tools—they’re clinical value creators.
• They improve diagnosis speed and accuracy.
• They teach clinicians at the point of care.
• They create institutional knowledge that persists beyond individual experts. Bottom Line

Start DMTs only in areas you know deeply, commit to daily operation, build redundancy, and focus on clinical impact rather than administrative metrics.

The most successful DMTs solve real diagnostic uncertainty while teaching the next generation of clinicians.